In a significant development for the UK’s medical cannabis sector, Aurora Cannabis Inc., a Canadian frontrunner in the global medical cannabis market, has unveiled a partnership with Script Assist, a pioneering medical cannabis prescription platform based in the UK.
This alliance is set to revolutionize the way medical cannabis is prescribed and accessed by patients, marking a significant milestone in the journey towards improved patient care and accessibility.
Positioned as Global Leader in Medical Cannabis
Aurora Cannabis Inc. is renowned for its commitment to quality and innovation in the medical cannabis industry. With a diverse portfolio that spans various brands and products, Aurora stands at the forefront of the medical and recreational cannabis markets globally.
Headquartered in Edmonton, Alberta, the company’s mission is centered around opening the world to cannabis and aiding individuals in enhancing their quality of life through high-grade cannabis products.
Aurora’s product range is extensive, including medical cannabis brands such as MedReleaf, CanniMed, and Whistler Medical Marijuana Co, as well as consumer brands like Aurora Drift and San Rafael ’71.
With its subsidiary Aurora Europe GmbH, the company also plays a significant role in the European Union & UK markets, providing top-notch medical cannabis products.
Revolutionizing Medical Cannabis Prescription
The Script Assist platform emerges as a cutting-edge solution designed to facilitate the medical cannabis prescription process in the UK.
By integrating innovative technology with a patient-centric approach, Script Assist aims to provide seamless access to high-quality medical cannabis.
The platform is characterized by its user-friendly interface, offering features like transparent payment, tracking, and live inventory levels for effortless repeat requests.
With the introduction of the “Find a Doctor” feature, Script Assist further simplifies the journey for patients seeking medical cannabis, enabling them to connect with private doctors and access prescriptions efficiently.
A Synergistic Partnership for Improved Patient Care
The partnership between Aurora Cannabis and Script Assist is poised to significantly enhance the medical cannabis landscape in the UK. By combining Aurora’s premium cannabis products with Script Assist’s technological prowess, this collaboration aims to ensure that patients have access to the best possible treatment options.
Starting in March, Script Assist will introduce three new high-quality flower products from Aurora’s EU GMP-certified facilities in Canada, catering to a range of patient needs with options for high THC content as well as balanced THC/CBD products.
Commitment to Excellence and Accessibility
Trisha Cassidy, Managing Director of Aurora UK & Ireland, expressed enthusiasm about the partnership, highlighting the commitment to not only expanding access to medical cannabis but also to providing patients with valuable information and guidance throughout their treatment journey.
This collaboration reflects a shared vision of enhancing patient well-being and accessibility to premium medical cannabis products in the UK.
Transforming the Prescription Process
The Script Assist platform, with its “Find a Doctor” feature, represents a significant leap forward in streamlining the medical cannabis prescription process.
By enabling patients to effortlessly connect with specialist prescribing doctors, Script Assist and Aurora are setting new standards for convenience and accessibility in medical cannabis care.
Forward-Looking Statements and Future Prospects
While the partnership between Aurora Cannabis and Script Assist is forward-looking and subject to various risks and uncertainties, it underscores a collective ambition to improve the medical cannabis sector in the UK.
The collaboration is built on a foundation of innovation, quality, and patient care, aiming to navigate the challenges and capitalize on opportunities to enhance the availability and quality of medical cannabis.
A Bright Future for Medical Cannabis in the UK
The strategic partnership between Aurora Cannabis and Script Assist marks a pivotal moment in the evolution of the UK’s medical cannabis landscape.
By leveraging Aurora’s expertise in cannabis production and Script Assist’s innovative prescription platform, this collaboration is set to significantly improve access to medical cannabis for patients across the UK.
With a commitment to excellence, innovation, and patient care, Aurora Cannabis and Script Assist are poised to lead the way in transforming the medical cannabis sector, ensuring that patients receive the highest quality of care and treatment options available.
This partnership not only signifies a step forward in medical cannabis accessibility but also highlights the potential for continued growth and innovation in the industry, promising a brighter future for patients and practitioners alike.
DISCLAIMER
You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Dean is a freelance content writer who contributes to various Digital Media Companies and independent websites all over the world. He has over 20 years of financial industry experience, so it’s safe to say he’s well informed.
